Ventricular Assist Devices: - Vanderbilt University Medical Center
... • Commonly used on an outpatient basis for stage IIIb – IV heart failure • Milrinone and Dobutamine are the only FDA approved drugs for outpatient use • Not recommended for acute heart failure exacerbations in ischemic patients • Probable benefit in non-ischemic exacerbations • OPTIME-CHF JAMA ...
... • Commonly used on an outpatient basis for stage IIIb – IV heart failure • Milrinone and Dobutamine are the only FDA approved drugs for outpatient use • Not recommended for acute heart failure exacerbations in ischemic patients • Probable benefit in non-ischemic exacerbations • OPTIME-CHF JAMA ...
Right Heart Failure in Cardiac Surgical Patients
... 1. Understand the pathophysiology of right heart failure. 2. Recognize the differences between acute versus chronic right heart failure. 3. Describe treatment options. Right heart failure (RHF) is a clinical syndrome with multiple etiologies. Chronic RHF can be seen with severe left-sided heart fail ...
... 1. Understand the pathophysiology of right heart failure. 2. Recognize the differences between acute versus chronic right heart failure. 3. Describe treatment options. Right heart failure (RHF) is a clinical syndrome with multiple etiologies. Chronic RHF can be seen with severe left-sided heart fail ...
Ready for Review - Paramedic.EMSzone.com
... Coronary artery disease is the most common form of heart disease and the leading cause of death in adults in Europe. Cardiac rhythm disturbances or arrhythmias may arise from a variety of causes— they are not solely caused by AMI. Most cardiac arrest victims have evidence of atherosclerosis or other ...
... Coronary artery disease is the most common form of heart disease and the leading cause of death in adults in Europe. Cardiac rhythm disturbances or arrhythmias may arise from a variety of causes— they are not solely caused by AMI. Most cardiac arrest victims have evidence of atherosclerosis or other ...
Cardiac Resynchronisation Therapy
... improved quality of life, exercise capacity & ventricular function Trials with CRT +/- ICD (COMPANION) showed that with CRT alone the decrease in risk of death was insignificant Meta-analysis are inconclusive This trial was designed to assess the effect of CRT on mortality in patients with severe HF ...
... improved quality of life, exercise capacity & ventricular function Trials with CRT +/- ICD (COMPANION) showed that with CRT alone the decrease in risk of death was insignificant Meta-analysis are inconclusive This trial was designed to assess the effect of CRT on mortality in patients with severe HF ...
Cardiology Diagnostic Tools
... Radionuclide studies a. Used for Shunt detection b. Imaging for Acute MI c. Nuclear Angiography d. Perfusion Scanning Cardiac Catheterization and Selective Angiography a. Right and Left Heart used for Dx and Assessment of Congenital/Acquired Heart Disease i. Pressure and Oxygen Saturation in heart c ...
... Radionuclide studies a. Used for Shunt detection b. Imaging for Acute MI c. Nuclear Angiography d. Perfusion Scanning Cardiac Catheterization and Selective Angiography a. Right and Left Heart used for Dx and Assessment of Congenital/Acquired Heart Disease i. Pressure and Oxygen Saturation in heart c ...
CHF in the Elderly
... in those over 80 years old is common and include nonspecific systemic complaints, confusion, irritability, sleep disturbances and gastrointestinal disorders, such as anorexia, abdominal discomfort, nausea and diarrhea. ...
... in those over 80 years old is common and include nonspecific systemic complaints, confusion, irritability, sleep disturbances and gastrointestinal disorders, such as anorexia, abdominal discomfort, nausea and diarrhea. ...
Left Bundle Branch Block
... LBBB does not give symptoms in the absence of any other underlying heart abnormality, What extra tests are required? Patients with LBBB usually require a heart ultrasound, a Holter ECG monitor and a stress test such as an exercise tolerance test to try and exclude associated heart conditions. Will I ...
... LBBB does not give symptoms in the absence of any other underlying heart abnormality, What extra tests are required? Patients with LBBB usually require a heart ultrasound, a Holter ECG monitor and a stress test such as an exercise tolerance test to try and exclude associated heart conditions. Will I ...
EP Studies
... 6. Part 2: Subjects with a diagnosis of heart failure, ejection fraction < 35%, as determined by any method within 6 months of Screening. 7. Current diagnosis of atrial flutter. ...
... 6. Part 2: Subjects with a diagnosis of heart failure, ejection fraction < 35%, as determined by any method within 6 months of Screening. 7. Current diagnosis of atrial flutter. ...
Dias nummer 1
... Sudden cardiac death (SCD) in young adults is often caused by inherited heart disease. Until now the genetic diagnostic tools in patients with SCD or survivors after cardiac arrest have targeted the presumed phenotype which often can be difficult to define. We aimed to overcome these limitations by ...
... Sudden cardiac death (SCD) in young adults is often caused by inherited heart disease. Until now the genetic diagnostic tools in patients with SCD or survivors after cardiac arrest have targeted the presumed phenotype which often can be difficult to define. We aimed to overcome these limitations by ...
Sotalol Considerations for Use - American College of Cardiology
... Monitor serum creatinine, magnesium, potassium, heart rate, blood pressure; EKG. Has many drug interactions. Abrupt cessation my precipitate angina, MI, arrhythmias, or rebound HTN; discontinue by tapering over 1-2 weeks. ...
... Monitor serum creatinine, magnesium, potassium, heart rate, blood pressure; EKG. Has many drug interactions. Abrupt cessation my precipitate angina, MI, arrhythmias, or rebound HTN; discontinue by tapering over 1-2 weeks. ...
The acute and long-term effects of intracoronary Stem cell
... Revision received April 12, 2010. Accepted April 16, 2010. Abstract Aims Despite accumulated evidence that intracoronary bone marrow cell (BMC) therapy may be beneficial in acute myocardial infarction, there are only limited data available on the effectiveness of BMC's in chronic heart failure. The ...
... Revision received April 12, 2010. Accepted April 16, 2010. Abstract Aims Despite accumulated evidence that intracoronary bone marrow cell (BMC) therapy may be beneficial in acute myocardial infarction, there are only limited data available on the effectiveness of BMC's in chronic heart failure. The ...
Heart Disease - Hospice of the Shoals
... Heart Disease Hospice Admission Criteria Medical criteria listed below that would support hospice appropriateness include: (check all that apply) 1. At the time of initial certification or re-certification for Hospice ___Patient is being treated optimally with diuretics and vasodilators ___ACE inhib ...
... Heart Disease Hospice Admission Criteria Medical criteria listed below that would support hospice appropriateness include: (check all that apply) 1. At the time of initial certification or re-certification for Hospice ___Patient is being treated optimally with diuretics and vasodilators ___ACE inhib ...
Cardiology Jeopardy
... Q: Indications for biventricular pacemakerdefibrillator placement include NYHA class III or IV heart failure, a QRS width greater than 120 msec, and an ejection fraction less than or equal to this percent. ...
... Q: Indications for biventricular pacemakerdefibrillator placement include NYHA class III or IV heart failure, a QRS width greater than 120 msec, and an ejection fraction less than or equal to this percent. ...
Name: Dr
... symptoms and exercise capacity (6-minute hall walk distance), gain in ejection fraction as well as improvement of quality of life. In addition, we have demonstrated that biventricular pacing increases diastolic filling time, reduces pre-systolic time, reduces mitral regurgitation, resolve pulsus alt ...
... symptoms and exercise capacity (6-minute hall walk distance), gain in ejection fraction as well as improvement of quality of life. In addition, we have demonstrated that biventricular pacing increases diastolic filling time, reduces pre-systolic time, reduces mitral regurgitation, resolve pulsus alt ...
J Thorac Cardiovasc Surg
... clinically meaningful survival benefit and an improved quality of life. A left ventricular assist device is an acceptable alternative therapy in selected patients who are not candidates for cardiac transplantation.” One-year survival: 52% vs. 25% (p=0.002) Two-year survival: 23% vs. 8% (p=0.09) ...
... clinically meaningful survival benefit and an improved quality of life. A left ventricular assist device is an acceptable alternative therapy in selected patients who are not candidates for cardiac transplantation.” One-year survival: 52% vs. 25% (p=0.002) Two-year survival: 23% vs. 8% (p=0.09) ...
Slide () - AccessAnesthesiology
... AV sequential and atrial pacing are frequently employed during cardiac surgery as various degrees of heart block are often encountered perioperatively. Prolongation of the PR interval is seen in first-degree heart block here associated with the prolonged QRS complexes often seen during bundle branch ...
... AV sequential and atrial pacing are frequently employed during cardiac surgery as various degrees of heart block are often encountered perioperatively. Prolongation of the PR interval is seen in first-degree heart block here associated with the prolonged QRS complexes often seen during bundle branch ...
Defibrillators
... • In the heart ventricular fibrillation is a condition which can lead to asystole. • It is usually preceded by ventricular tachycardia (fast heart rhythm). ...
... • In the heart ventricular fibrillation is a condition which can lead to asystole. • It is usually preceded by ventricular tachycardia (fast heart rhythm). ...
Objectives Cardiovascular disease, congestive heart failure (CHF
... apparently relevant biomarkers are investigated (plasma procollagen, neurohumoral factors; imaging of collagen, type of fibrosis and cardiac sympathetic denervation) in hearts with infarction and/or a conduction abnormality (left bundle branch block; known to be corrected by CRT) (WP 2). Similarly, ...
... apparently relevant biomarkers are investigated (plasma procollagen, neurohumoral factors; imaging of collagen, type of fibrosis and cardiac sympathetic denervation) in hearts with infarction and/or a conduction abnormality (left bundle branch block; known to be corrected by CRT) (WP 2). Similarly, ...
New Options in Heart Failure for the Primary Care
... with advanced heart failure resulted in a clinically meaningful survival benefit and an improved quality of life. • A left ventricular assist device is an acceptable alternative therapy in selected patients who are not candidates for cardiac transplantation.” • One-year survival: 52% vs. 25% (p=0.00 ...
... with advanced heart failure resulted in a clinically meaningful survival benefit and an improved quality of life. • A left ventricular assist device is an acceptable alternative therapy in selected patients who are not candidates for cardiac transplantation.” • One-year survival: 52% vs. 25% (p=0.00 ...
medicare expands coverage of cardic rehab to chf
... In a recent study published in the Journal of the American College of Cardiology, it was concluded that cardiac rehab and counseling is extremely beneficial for heart failure patients. The benefits include: • Increase in exercise • Minimize symptoms of heart failure • Reduce behavioral risk factors ...
... In a recent study published in the Journal of the American College of Cardiology, it was concluded that cardiac rehab and counseling is extremely beneficial for heart failure patients. The benefits include: • Increase in exercise • Minimize symptoms of heart failure • Reduce behavioral risk factors ...
Chapter 20
... a new mitral regurgitation murmur (II/VI), an S3, jugular venous distention to his earlobe, and ascites. He did not have crackles or decreased breath sounds. ...
... a new mitral regurgitation murmur (II/VI), an S3, jugular venous distention to his earlobe, and ascites. He did not have crackles or decreased breath sounds. ...
Cardiac contractility modulation
.jpg?width=300)
Cardiac contractility modulation (CCM) is a treatment for patients with moderate to severe left ventricular systolic heart failure (NYHA class II–IV). The short- and long-term use of this therapy enhances both the strength of ventricular contraction and the heart’s pumping capacity. The CCM mechanism is based on stimulation of the cardiac muscle by non-excitatory electrical signals (NES). CCM treatment is delivered by a pacemaker-like device that applies the NES, adjusted to and synchronized with the electrical action in the cardiac cycle.In CCM therapy, electrical stimulation is applied to the cardiac muscle during the absolute refractory period. In this phase of the cardiac cycle, electrical signals cannot trigger new cardiac muscle contractions, hence this type of stimulation is known as a non-excitatory stimulation. However, the electrical CCM signals increase the influx of calcium ions into the cardiac muscle cells (cardiomyocytes). In contrast to other electrical stimulation treatments for heart failure, such as pacemaker therapy or implantable cardioverter defibrillators (ICD), CCM does not affect the cardiac rhythm directly. Rather, the aim is to enhance the heart’s natural contraction (the native cardiac contractility) sustainably over long periods of time. Furthermore, unlike most interventions that increase cardiac contractility, CCM is not associated with an unfavorable increase in oxygen demand by the heart (measured in terms of Myocardial Oxygen Consumption or MVO2). This may be explained by the beneficial effect CCM has in improving cardiac efficiency. A meta-analysis in 2014 and an overview of device-based treatment options in heart failure in 2013 concluded that CCM treatment is safe, that it is generally beneficial to patients and that CCM treatment increases the exercise tolerance (ET) and quality of life (QoL) of patients. Furthermore, preliminary long-term survival data shows that CCM is associated with lower long-term mortality in heart failure patients when compared with expected rates among similar patients not treated with CCM.